Prognostic Factors of Recurrent Cervical Cancer Stage IA2–IIA2: A Post-Surgical Treatment Analysis
Abstract
Background: Cervical cancer is the most common female reproductive organ malignancy. Despite the prompt diagnosis and proper management based on the disease’s stage, the recurrent rate remains high, ranging from 18 to 44.3%. Prognostic factor detection may be the first step in reducing recurrent disease. To our knowledge, there are no studies that report the recurrence rate of cervical cancer and the prognostic factors in Indonesia yet. This study aims to report the recurrent rate of cervical cancer stage IA2–IIA2 and the prognostic factors.
Methods: This is a retrospective cohort study. Histopathology results from 382 cervical cancer stage IA2–IIA2 patients who underwent radical hysterectomy and pelvic lymphadenectomy were reviewed. Bivariate analysis was performed to compare recurrent disease based on 7 prognostic factors: lymph node status, tumor size, depth of stromal invasion, lymphovascular space invasion (LVSI), parametrial involvement, histology type, and vaginal resection margin status.
Results: Most cervical cancer patients with stage IA2–IIA2 were more than 40 years old, with a mean age was 52 years. The recurrent rate was 12%. Prognostic factors that were significantly associated with recurrence were tumor size ≥ 4 cm; RR 2.242 (95% CI 1.161–4.332) and LVSI; RR 2.037 (95% CI 1.039–3.994).
Conclusions: The recurrence rate of cervical cancer stage IA2–IIA2 in Dr. Cipto Mangunkusumo National Hospital was 12%. Prognostic factors that were significantly associated with recurrence were tumor size ≥ 4 cm and LVSI.
Keywords
DOI: 10.33371/ijoc.v18i4.1141
Article Metrics
Abstract View: 212, 
PDF Download: 96
References
World Health Organization. Indonesia Fact Sheets 2020. Glob Cancer Obs 2020. 2020;858.
Bhatla N, Berek JS, Cuello Fredes M, et al. Revised FIGO staging for carcinoma of the cervix uteri. Int J Gynecol Obstet. 2019;145(1):129-135.
Hacker NF. Berek and Hacker’s Gynecologic Oncology. 6th Editio. Philadeplphia: Wolters Kluwer Health/Lippincott Williams & Wilkins; 2010.
Barbara L. Hoffman, MD John O. Schorge, MD Joseph I. Schaffer, MD Lisa M. Halvorson, MD Karen D. Bradshaw, MD F. Gary Cunningham M. William’s Gynecology. The McGraw-Hill Companies, Inc; 2012.
Kwon J, Eom KY, Kim YS, et al. The prognostic impact of the number of metastatic lymph nodes and a new prognostic scoring system for recurrence in early-stage cervical cancer with high risk factors: A multicenter cohort study (krog 15-04). Cancer Res Treat. 2018;50(3):964-974.
Zhou J, Zhang WW, Wu SG, et al. The prognostic value of histologic subtype in node-positive early-stage cervical cancer after hysterectomy and adjuvant radiotherapy. Int J Surg. 2017;44:1-6.
Polterauer S, Grimm C, Hofstetter G, et al. Nomogram prediction for overall survival of patients diagnosed with cervical cancer. Br J Cancer. 2012;107(6):918-924.
Biewenga P, Van Der Velden J, Mol BWJ, et al. Prognostic model for survival in patients with early stage cervical cancer. Cancer. 2011;117(4):768-776.
Horn LC, Höhn AK, Hentschel B, Fischer U, Bilek K, Brambs CE. Prognostic relevance of low-grade versus high-grade FIGO IB1 squamous cell uterine cervical carcinomas. J Cancer Res Clin Oncol. 2019;145(2):457-462.
Hartman CA, Teixeira JC, Barbosa SB, Figueiredo SM, Andrade LALDA, Bastos JFB. Analysis of Conservative Surgical Treatment and Prognosis of Microinvasive Squamous Cell Carcinoma of the Cervix Stage IA1: Results of Follow-Up to 20 Years. Int J Gynecol Cancer. 2017;27(2):357-363.
Derks M, Van Der Velden J, De Kroon CD, et al. Surgical Treatment of Early-Stage Cervical Cancer: A Multi-Institution Experience in 2124 Cases in The Netherlands Over a 30-Year Period. Int J Gynecol Cancer. 2018;28(4):757-763.
Hanprasertpong J, Jiamset I. Late Recurrence of Early Stage Cervical Cancer more than 3 Years after Radical Hysterectomy with Pelvic Node Dissection. Oncol Res Treat. 2017;40(5):270-276.
Rose PG, Java JJ, Whitney CW, Stehman FB, Lanciano R, Thomas GM. Locally advanced adenocarcinoma and adenosquamous carcinomas of the cervix compared to squamous cell carcinomas of the cervix in Gynecologic Oncology Group trials of cisplatin-based chemoradiation. Gynecol Oncol. 2014;135(2):208-212.
Rose PG, Java J, Whitney CW, et al. Nomograms predicting progression-free survival, overall survival, and pelvic recurrence in locally advanced cervical cancer developed from an analysis of identifiable prognostic factors in patients from NRG oncology/gynecologic oncology group randomized t. J Clin Oncol. 2015;33(19):2136-2142.
Yu Q, Lou XM, He Y. Prediction of local recurrence in cervical cancer by a Cox model comprised of lymph node status, lymph-vascular space invasion, and intratumoral Th17 cell-infiltration. Med Oncol. 2014;31(1):1-6.
de Foucher T, Bendifallah S, Ouldamer L, et al. Patterns of recurrence and prognosis in locally advanced FIGO stage IB2 to IIB cervical cancer: Retrospective multicentre study from the FRANCOGYN group. Eur J Surg Oncol. 2019;45(4):659-665.
Verleye L, Vergote I, Reed N, Ottevanger PB. Quality assurance for radical hysterectomy for cervical cancer: The view of the European Organization for Research and Treatment of Cancer - Gynecological Cancer Group (EORTC-GCG). Ann Oncol. 2009;20(10):1631-1638.
Wang R, Tao X, Wu X, Jiang H, Xia H. The Number of Removed Pelvic Lymph Nodes as a Prognostic Marker in FIGO Stage IB1 Cervical Cancer with Negative Lymph Nodes. J Minim Invasive Gynecol. 2019.
Xie L, Chu R, Wang K, et al. Prognostic Assessment of Cervical Cancer Patients by Clinical Staging and Surgical-Pathological Factor: A Support Vector Machine-Based Approach. Front Oncol. 2020;10(August):1-11.
College of American Pathologists. Protocol for the Examination of Specimens From Patients With Primary Carcinoma of the Uterine Cervix [Internet]. Version UterineCervix 4.1.0.0. 2018;(August):1-18. Available from: www.cap.org/cancerprotocols.
DiSaia PJ, Creasman WT. Clinical Gynecologic Oncology.; 2007. doi:10.1016/B978-0-323-03978-9.X5001-1
Zreik TG, Chambers JT, Chambers SK. Parametrial involvement, regardless of nodal status: A poor prognostic factor for cervical cancer. Obstet Gynecol. 1996;87(5):741-746.
Burghardt E, Baker J, Tulusan AH, Haas J. Results of surgical treatment of 1028 cervical cancers studied with volumetry. Cancer. 1992;70(3):648-655.
Vinh-Hung V, Bourgain C, Vlastos G, et al. Prognostic value of histopathology and trends in cervical cancer: A SEER population study. BMC Cancer. 2007;7:1-13.
Seamon LG, Java JJ, Monk BJ, et al. Impact of tumour histology on survival in advanced cervical carcinoma: An NRG Oncology/Gynaecologic Oncology Group Study. Br J Cancer. 2018;118(2):162-170.
Katanyoo K, Sanguanrungsirikul S, Manusirivithaya S. Comparison of treatment outcomes between squamous cell carcinoma and adenocarcinoma in locally advanced cervical cancer. Gynecol Oncol. 2012;125(2):292-296.
Kim YJ, Lee KJ, Park KR, et al. Prognostic analysis of uterine cervical cancer treated with postoperative radiotherapy: Importance of positive or close parametrial resection margin. Radiat Oncol J. 2015;33(2):109-116.
McCann GA, Taege SK, Boutsicaris CE, Phillips GS, Eisenhauer EL, Fowler JM, et al. The impact of close surgical margins after radical hysterectomy for early-stage cervical cancer. Gynecol Oncol. 2013 Jan;128(1):44-48.
Refbacks
- There are currently no refbacks.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Email this article 
